In conjunction with this leadership change, Bob Lally, who has been serving as the Senior Vice President of Finance & Operations since July 2025, has been appointed as the new Principal Accounting Officer effective March 20, 2026. Mr. Lally brings a wealth of experience to this role, having previously held senior finance positions at Prevail Therapeutics Inc. and Ikena Oncology, Inc. His appointment is expected to ensure continuity in the company's financial operations and oversight.
The company has not indicated any material plans or contracts associated with Mr. Lally's appointment, and there are no disclosed family relationships between Mr. Lally and any current or former directors or executive officers of the company. Furthermore, Mr. Lally is not involved in any transactions that would require disclosure under Item 404(a) of Regulation S-K.
This leadership transition comes at a time when ImageneBio is focusing on its strategic objectives and operational execution. The company is committed to maintaining strong governance controls and ensuring that its financial reporting remains robust and compliant with regulatory standards. As an emerging growth company, ImageneBio continues to navigate the complexities of the biotechnology sector, and these changes in leadership are part of its ongoing efforts to enhance its operational effectiveness and strategic outlook.
